secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0000950103-25-012514
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed
--------------------------------------------------------------------------------

- LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).
- LOTIS-5 Phase 3 trial fully enrolled; topline data expected 1H 2026 for potential sBLA submission.
- ZYNLONTA Phase 2 IIT in r/r MZL showed 69.2% CR and 84.6% ORR (N=26 evaluable); CR maintained in 17/18 patients.
- PSMA-targeting ADC progresses IND-enabling activities; seeking research collaborations.
- Cash runway expected into 2028; company continues to grow ZYNLONTA revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325012514/0000950103-25-012514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325012514/dp235214_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-012514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer